Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T. Uenami

P3.cr-20 the Effect of Pembrolizumab in EGFR Mutated Lung Adenocarcinoma Patients With PD-L1 Overexpression: Two Cases Report

Journal of Thoracic Oncology

English

Related publications

P3.cr-02 SBRT of Lung Primary After Complete Resolution of Metastatic Disease in Case of EGFR Mutated Adenocarcinoma Lung: A Case Report

Journal of Thoracic Oncology

English

Multiple Primary Lung Cancers Containing Adenocarcinoma With EGFR Gene Mutation and Adenocarcinoma With Strong PD-L1 Positivity

Japanese Journal of Lung Cancer

English

P3.cr-09 MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma" With "MET Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma

Journal of Thoracic Oncology

English

P1.13-20 MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma

Journal of Thoracic Oncology

English

P2.03-030 Cumulative Smoking Dose Affects the Clinical Outcomes of EGFR-Mutated Lung Adenocarcinoma Patients Treated With EGFR-TKIs

Journal of Thoracic Oncology

English

Risk Factors of Brain Metastasis During the Course of EGFR-TKIs Therapy for Patients With EGFR-mutated Advanced Lung Adenocarcinoma

Oncotarget

Oncology

2016

English

The Role of Pembrolizumab in the Treatment of PD-L1 Expressing Gastric and Gastroesophageal Junction Adenocarcinoma

Therapeutic Advances in Gastroenterology

Gastroenterology

2019

English

P2.09-04 PD-L1 Expression in Primary Lung Adenocarcinoma and Its Relation With EGFR / KRAS Mutation and Clinicopathological Features

Journal of Thoracic Oncology

English

MicroRNA-155-5p Suppresses PD-L1 Expression in Lung Adenocarcinoma

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T. Uenami

P3.cr-20 the Effect of Pembrolizumab in EGFR Mutated Lung Adenocarcinoma Patients With PD-L1 Overexpression: Two Cases Report

Related publications

P3.cr-02 SBRT of Lung Primary After Complete Resolution of Metastatic Disease in Case of EGFR Mutated Adenocarcinoma Lung: A Case Report

Multiple Primary Lung Cancers Containing Adenocarcinoma With EGFR Gene Mutation and Adenocarcinoma With Strong PD-L1 Positivity

P3.cr-09 MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma" With "MET Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma

P1.13-20 MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma

P2.03-030 Cumulative Smoking Dose Affects the Clinical Outcomes of EGFR-Mutated Lung Adenocarcinoma Patients Treated With EGFR-TKIs

Risk Factors of Brain Metastasis During the Course of EGFR-TKIs Therapy for Patients With EGFR-mutated Advanced Lung Adenocarcinoma

The Role of Pembrolizumab in the Treatment of PD-L1 Expressing Gastric and Gastroesophageal Junction Adenocarcinoma

P2.09-04 PD-L1 Expression in Primary Lung Adenocarcinoma and Its Relation With EGFR / KRAS Mutation and Clinicopathological Features

MicroRNA-155-5p Suppresses PD-L1 Expression in Lung Adenocarcinoma